These impressive anti-PDAC activities together with their strong anti-migratory and anti-invasive activities, in vitro and strong inhibition of MiaPaCa-2 tumor growth suggest that gal and its analogs have great potential either as monotherapies or in combination with current elective PDAC drugs for the treatment of various forms of pancreatic cancer. Here, GAL is linked to pancreatic neoplasm.